Xponance Inc. Boosts Stock Position in Masimo Co. (NASDAQ:MASI)

Xponance Inc. increased its stake in shares of Masimo Co. (NASDAQ:MASI) by 4.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,025 shares of the medical equipment provider’s stock after buying an additional 299 shares during the quarter. Xponance Inc.’s holdings in Masimo were worth $1,161,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Masimo by 41.2% during the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock worth $900,860,000 after acquiring an additional 1,970,883 shares during the period. Corient Private Wealth LLC boosted its holdings in Masimo by 8,847.1% in the 4th quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider’s stock valued at $57,472,000 after purchasing an additional 343,797 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after purchasing an additional 262,370 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Masimo during the 4th quarter worth approximately $33,716,000. Finally, Assenagon Asset Management S.A. raised its position in shares of Masimo by 916.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 216,051 shares of the medical equipment provider’s stock valued at $35,713,000 after buying an additional 194,788 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Wall Street Analyst Weigh In

MASI has been the subject of several analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Piper Sandler raised their price objective on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Wells Fargo & Company upped their target price on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Raymond James lifted their price target on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Masimo currently has a consensus rating of “Moderate Buy” and an average price target of $194.80.

Insider Buying and Selling at Masimo

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now directly owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by corporate insiders.

Masimo Price Performance

MASI opened at $165.82 on Monday. The firm has a market cap of $8.95 billion, a price-to-earnings ratio of 114.36 and a beta of 1.04. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock’s 50-day moving average price is $174.99 and its 200 day moving average price is $159.82. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to analysts’ expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. As a group, sell-side analysts expect that Masimo Co. will post 4.1 earnings per share for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.